

REFERENECS

1. Bowman WC, Rand D. The immune system and inflammatory mechanisms. In: Immunosuppressant. 2nd ed. London: Blackwell Scientific Publications, 1980: 13.1-13.35.
2. Gallin JI, Snyderman R. Overview. In: Inflammation. Basic Principles and Clinical Correlates. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 1-4.
3. Guyton AC, Hall JE. Resistance of the body to infection. Leukocytes, granulocytes, the monocyte-macrophage system, and inflammation. In: Textbook of Medical Physiology. 10th ed. Philadelphia: WB Saunders Company, 2000: 392-401.
4. Benjamini E, Coico R, Sunshine G. Elements of innate and acquired immunity. In: Immunology. A Short Course. 4th ed. New York: Wiley-Liss Inc, 2000: 17-39.
5. Fantone JC, Ward PA. Inflammation. In: Rubin E, Farber JL, editors. Pathology. 3rd ed. Philadelphia: Lippincott-Raven, 1999: 36-75.
6. Lee JB, Katayama S. Inflammation and Nonsteroidal Anti-inflammatory Drugs. In: Smith CM, Reynard AM, editors. Textbook of Pharmacology. Philadelphia, WB Saunders Company, 1992: 401-435.
7. Collins T. Acute and chronic inflammation. In: Cotran RS, Kumar V, Collins T, editors. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders, 1999: 50-88.

8. Furst DE, Munster T. Nonsteroidal Anti-inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, and Drugs Used in Gout. In: Katzung BG, editor. *Basic and Clinical Pharmacology*. 8th ed. New York: McGraw-Hill Companies, 2001: 596-623.
9. Hurley JV. Terminations of acute inflammation. In: *Acute inflammation*. 2nd ed. New York: Churchill Livingstone, 1983: 133-147.
10. Dale HH, Laidlaw PP. Further observations on the action of beta-imminazolethylamine. *J Physiol* 1911; 43: 182-195.
11. Vane JR. Prostaglandins in the inflammatory response. In: Lepow IH, Ward PA, editors. *Mechanism and Control. Inflammation*. New York: Academic Press, 1972: 261-279.
12. Babe KS, Serafin WE. Histamine, Bradykinin, and their antagonists. In: Hardman JG, Limbird LE, editors. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. New York: McGraw-Hill Companies, 1999: 581-600.
13. Owen DA. Inflammation-- Histamine and 5-hydroxytryptamine. *Br Med Bull* 1987; 43(2): 256-269.
14. Abbas AK, Lichtman AH, Pober JS. Effector mechanism of immunoglobulin E-initiated immune reactions. In: *Immunology*. 3rd ed. Philadelphia: WB Saunders Company, 1997: 297-312.
15. Chandrasoma P, Taylor CR. The host response to injury. In: *Concise Pathology*. Connecticut: Appleton & Lange, 1998: 35-104.

16. Rang HP, Dale MM, Ritter JM. Other peripheral mediators: 5-hydroxytryptamine and purines. In: Pharmacology. 3rd ed. London: Churchill Livingstone, 1995: 177-190.
17. Reid I. Vasoactive peptides. In: Katzung BG, editor. Basic Clinical Pharmacology. 8th ed. New York: McGraw-Hill Companies, 2001: 292-310.
18. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. *Pain* 2000; 87(1): 1-5.
19. Regoli D. Kinins. *Br Med Bull* 1987; 43(2): 270-284.
20. Cooper NR. Biology of the complement system. In: Gallin JI, Snyderman R, editors. Inflammation. Basic Principles and Clinical Correlates. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 281-315.
21. Campbell WB, Haluska PV. Lipid-derived autacoids: Eicosanoids and platelet-activating factor. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw Hill Companies, 1999: 601-616.
22. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. *Br Med Bull* 1987; 43(2): 285-296.
23. Griffith RJ. Prostaglandins and inflammation. In: Gallin JI, Snyderman R, editors. Inflammation. Basic Principles in Therapeutics. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 349-360.
24. Hawkey CJ. COX-2 inhibitors. *Lancet* 1999; 353(9149): 307-314.

25. Penrose JF, Austen KF, Lam BK. Leukotrienes. In: Gallin JI, Snyderman R, editors. *Inflammation. Basic Principles and Clinical Correlates*. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 361-372.
26. Prescott SM, McIntyre TM, Zimmerman GA. Platelet-activating factor: A phospholipid mediator of inflammation. In: Gallin JI, Snyderman R, editors. *Inflammation. Basic Principles and Clinical Correlates*. 3rd ed. New York: Lippincott Williams & Wilkins, 1999: 387-396.
27. Vargaftig BB, Braquet PG. PAF-acether today--relevance for acute experimental anaphylaxis. *Br Med Bull* 1987; 43(2): 312-335.
28. Sunday JS, Patel DD, Haynes BF. Cytokine in normal and Pathogenic inflammatory response. In: Gallin JI, Snyderman R, editors. *Inflammation. Basic Principles and Clinical Correlates*. 3rd ed. New York: Lippincott Williams & Wilkins, 1999: 433-442.
29. Janeway CA, Travers P, Walport M, Capra JD. Host defense against infection. In: *Immunobiology. The Immune System in Health and Disease*. 4th ed. New York: Garland Publishing, 1999: 363-415.
30. Insel PA. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of Gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. New York: McGraw-Hill Companies, 1999: 617-658.
31. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. *Trends Pharmacol Sci* 1997; 18(1): 30-34.

32. Antonio MA, Souza Brito AR. Oral anti-inflammatory and anti-ulcerogenic activities of a hydroalcoholic extract and partitioned fractions of *Turnera ulmifolia* (Turneraceae). *J Ethnopharmacol* 1998; 61(3): 215-228.
33. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. *J Pharm Pharm Sci* 2000; 3(1): 137-155.
34. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal antiinflammatory drugs and aspirin--analyzing the scores. *Pharmacotherapy* 1985; 5(1): 30-38.
35. Schimmer BP, Parker KL. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormone. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill Companies, 1999: 1459-1485.
36. Vazquez B, Avila G, Segura D, Escalante B. Antiinflammatory activity of extracts from *Aloe vera* gel. *J Ethnopharmacol* 1996; 55(1): 69-75.
37. Langenegger T, Michel BA. Drug treatment for rheumatoid arthritis. *Clin Orthop* 1999;(366):22-30.
38. Case JP. Old and new drugs used in rheumatoid arthritis: A historical perspective. Part II: the newer drugs and drug strategies. *Am J Ther* 2001; 8(3): 163-179.
39. Emery P. Leflunomide: A new DMARD for rheumatoid arthritis. *Hospital Medicine* 2000; 61(5): 344-347.
40. Sedgwick AD, Willoughby DA. Animal models for testing drugs on inflammatory and hypertensively reactions. In: Dale MM, Foreman JC, editors. Textbook of Immunology. Oxford: Blackwell Scientific Publications, 1989: 253-261.

41. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. *J Steroid Biochem* 1982; 16(6): 779-786.
42. Young JM, Spires DA, Bedord CJ, Wagner B, Ballaron SJ, De Young LM. The mouse ear inflammatory response to topical arachidonic acid. *J Invest Dermatol* 1984; 82(4): 367-371.
43. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drug. *Proc Soc Exp Biol Med* 1962; 11: 544-547.
44. Di Rosa M. Biological properties of carrageenan. *J Pharm Pharmacol* 1972; 24(2): 89-102.
45. Di Rosa M, Willoughby DA. Screens for anti-inflammatory drugs. *J Pharm Pharmacol* 1971; 23(4): 297-298.
46. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. *J Pharmacol Exp Ther* 1969; 166(1): 96-103.
47. Dimartino MJ, Campbell GK, Jr., Wolff CE, Hanna N. The pharmacology of arachidonic acid-induced rat paw edema. *Agents Actions* 1987; 21(3-4): 303-305.
48. Meire R, Schuler W, Desaulles P. Zur Frage des Mechanismus der Hemmung des Bindegewebswachstums durch Cortisone. *Experientia* 1950; 6: 469-471.

49. Swingle KF, Shideman FE. Phases of the inflammatory response to subcutaneous implantation of a cotton pellet and their modification by certain anti-inflammatory agents. *J Pharmacol Exp Ther* 1972; 183(1): 226-234.
50. Bessey OA, Lowry OH, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. *J Biol Chem* 1946; 164: 321-329.
51. Ismail TS, Gopalakrishnan S, Begum VH, Elango V. Anti-inflammatory activity of *Salacia oblonga* Wall. and *Azima tetracantha* Lam. *J Ethnopharmacol* 1997; 56(2): 145-152.
52. Nishikaze O, Takita H, Takase T. Activity of newly discovered protease in carrageenan-induced inflammation in rats. In: *Connective Tissue; Skin and Bone; Survey and Transplantation*. IRIC Medical Science, Biochemistry 8, 1980: 725-725.
53. Valle JD, Todisco A. Gastric secretion. In: Yamada T, Alper DH, editors. *Textbook of Gastroenterology*. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 278-329.
54. Milton AS. Prostaglandins and fever. *Prog Brain Res* 1998; 115: 129-139.
55. Collier HO, Dinneen LC, Johnson CA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. *Br J Pharmacol* 1968; 32(2): 295-310.
56. Taber RI, Greenhouse DD, Rendell JK, Irwin S. Agonist and antagonist interactions of opioids on acetic acid-induced abdominal stretching in mice. *J Pharmacol Exp Ther* 1969; 169(1): 29-38.

57. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. *Pain* 1987; 30(1): 103-114.
58. Atkins E, Bodel P. Fever. In: Zweifach WB, Grant L, Mccluskey RT, editors. *The Inflammatory Process*. 2nd ed. New York: Academic Press, 1974: 500.
59. Teotino UM, Friz LP, Ganduni A, Bella DD. Thio derivatives of 2,3-dihydro-4H-1,3-benzoxazin-4-one synthesis and pharmacological properties. *J Med Chem* 1963; 6: 248-250.
60. Martin ML, Moran A, Carron R, Montero MJ, San Roman L. Antipyretic activity of alpha- and beta- santonin. *J Ethnopharmacol* 1988; 23(2-3): 285-290.
61. Sautebin L. Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy. *Fitoterapia* 2000; 71 Suppl 1: S48-S57.
62. O-urai S. "Anti-inflammatory activity and effect on gastric mucosa of mehtanol extract from the bark of *Garcinia speciosa*". M.S. Thesis, Chiang Mai University, 2000.
63. Koo KL, Ammit AJ, Tran VH, Duke CC, Roufogalis BD. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. *Thromb Res* 2001; 103(5): 387-397.
64. Tjendraputra E, Tran VH, Liu-Brennan D, Roufogalis BD, Duke CC. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. *Bioorg Chem* 2001; 29(3): 156-163.
65. Yoshikawa M, Hatakeyama S, Taniguchi K, Matuda H, Yamahara J. 6-Gingesulfonic acid, a new anti-ulcer principle, and gingerglycolipids A, B and

C, there new monoacyldigalactosylglycerols, from *Zingiberis rhizoma* originating in Taiwan. *Pharm Bull* 1992; 40(8): 2239-2241.

66. Kositchaiwat C, Kositchaiwat S, Havanondha. *Curcuma longa* Linn. in the treatment of gastric ulcer comparison to liquid antacid: a control clinical trial. *J Med Assoc Thai* 1993; 76(11): 601-605.
67. Yegananarayan R, Saraf AP, Balwani JH. Comparison of anti-inflammatory activity of various extracts of *Curcuma longa* (Linn.). *Indian J Med Res* 1976; 64(4): 601-608.
68. Sen T, Ghosh TK, Chaudhuri AK. Studies on the mechanism of anti-inflammatory and anti-ulcer activity of *Pluchea indica* probable involvement of 5-lipoxygenase pathway. *Life Sci* 1993; 52(8): 737-743.
69. ก่องกานดา ชยามฤต. *สมุนไพรไทย*. กรุงเทพฯ: บริษัทไคมอนด์ พรินติ้ง จำกัด, 2540: หน้า 61.
70. จินดาพร ภูมิพัฒนางษ์. *เภสัชเวทกับตำรายาแผนโบราณ*. กรุงเทพฯ: โรงพิมพ์องค์การสงเคราะห์ทหารผ่านศึก. 2539: หน้า 331.
71. พร้อมจิต ศรีลัมพ์. *สารานุกรมสมุนไพร เล่ม 1 สมุนไพรสวนสิริรุกขชาติ*. กรุงเทพฯ: คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล. 2543: หน้า 93.
72. มณฑิรา ตันท์เกยูร และโสภิต ธรรมอารี. *การพัฒนาสมุนไพรด้านสาธารณสุขสมัยกรุงรัตนโกสินทร์ เล่ม 1*. กรุงเทพฯ: สำนักงานอธิการบดี จุฬาลงกรณ์มหาวิทยาลัย, 2524: หน้า 650.
73. สมพร (ภูติยานันต์) หิรัญรามเดช. *คู่มือสมุนไพรใกล้ตัว ตอนที่ 2*. เชียงใหม่: คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่, 2525: หน้า 107.
74. พะยอม ต้นติวัฒน์. *สมุนไพร*. กรุงเทพฯ: สมาคมสมุนไพรแห่งประเทศไทย, 2521: หน้า 1-2.

75. Evan WC. Trease and Evans Pharmacognosy. 14th ed. Nothingham: Saunders Company Limited, 1996.
76. สายสนม กิตติขจร.หมวดที่ 1 ว่าด้วยสรรพคุณของต้นไม้ต่างๆ ที่นำมาปรุงยา. ตำราสรรพคุณสมุนไพรยาไทยแผนไทย. กรุงเทพฯ: โรงพิมพ์ส่วนท้องถิ่น กรมการปกครอง. 2526: หน้า 213.
77. สนั่น ศุภธิรกุล. สมุนไพรที่มีส่วนประกอบเป็นกัมเรซินและโอเลโอเรซิน. สมุนไพรจากผลิตภัณฑ์ของพืช. สงขลา: คณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์, 2540: หน้า 110-111.
78. Duke JA. Handbook of Medical Herbs. New York: Library of Congress, 1985.
79. เสี่ยม พงษ์บุญรอด. ไม้เทศเมืองไทย สรรพคุณยาเทศและยาไทย. กรุงเทพฯ: โรงพิมพ์กรุงธน. 2522: หน้า 462-463.
80. วุฒิ วุฒิชรมาเวช. เกษกรรมไทย รวมสมุนไพร. กรุงเทพฯ: โอ. เอส. พรินติ้ง เฮ้าส์, 2537: หน้า 359.
81. Asano J, Chiba K, Tada M, Yoshii T. Cytotoxic xanthenes from *Garcinia hanburyi*. *Phytochemistry* 1996; 41(3): 815-820.
82. Chairungsrilered N, Taakeuchi K, Ohizumi Y. Mangostanol, a prenyl xanthone from *Garcinia mangostana* . *Phytochemistry* 1996; 43: 1099-1102.
83. Likhiwitayawuid K, Phadungcharoen T, Mahidol C, Ruchirawat S. 7-O-methylgarcinone E from *Garcinia cowa*. *Phytochemistry* 1997; 45: 1299-1301.
84. Iwu MM, Anyanwu BN. Phytotheraprutic profile of Nigerian Herb: 1. Anti-inflammatory and anti-arthritic agents. *J Ethnopharmacol* 1982; 6: 263-274.

85. Iwu MM, Igboko OA, Tempesta MS. Biflavonoid constituent of *Garcinia kola* roots. *Fitoterapia* 1990; 61: 178-181.
86. Bradide VB. Antiinflammatory effect of kolaviron, a biflavonoid extract of *Garcinia kola*. *Fitoterapia* 1993; 64: 433-436.
87. Ibiroonke GF, Olaleye SB, Balogun O, Aremu A. Effects of diets containing seeds of *Garcinia kola* (Heckel) on gastric acidity and experimental ulceration in rats. *Phytother Res* 1997; 11: 312-313.
88. Minano FJ, Serrano JS, Pascual J, Sancibrian M. Effects of GABA on gastric acid secretion and ulcer formation in rats. *Life Sci* 1987; 41(13): 1651-1658.
89. Nakamura H, Shimoda A, Ishii K, Kadokawa T. Central and peripheral analgesic action of non-acidic non-steroidal anti-inflammatory drugs in mice and rats. *Arch Int Pharmacodyn Ther* 1986; 282(1): 16-25.
90. Sertie JA, Basile AC, Panizza S, Matida AK, Zelnik R. Anti-inflammatory activity and subacute toxicity of artemetin. *Planta Med* 1990; 56(1): 36-40.
91. Singh B, Gambhir SS, Pandey VB, Joshi VK. Anti-inflammatory activity of *Echinops Echinatus*. *J Ethnopharmacol* 1989; 25(2): 189-199.
92. Chairungsrilered N, Furukawa K, Ohta T, Nozoe S. Histaminergic and serotonergic receptor blocking substances from the medicinal plant *Garcinia mangostana*. *Planta Med* 1996; 62(5): 471-472.
93. Carlson RP, O'Neill-Davis L, Chang J, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. *Agents Actions* 1985; 17(2): 197-204.

94. Ferrandiz ML, Alcaraz MJ. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. *Agents Actions* 1991; 32(3-4): 283-288.
95. Crunkhorn P, Meacock SC. Mediators of the inflammation induced in the rat paw by carrageenin. *Br J Pharmacol* 1971; 42(3): 392-402.
96. Hirschelmann R, Bekemeier H. Effects of catalase, peroxidase, superoxide dismutase and 10 scavengers of oxygen radicals in carrageenin edema and in adjuvant arthritis of rats. *Experientia* 1981; 37(12): 1313-1314.
97. Camp RD, Coutts AA, Greaves MW, Kay AB, Walport MJ. Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. *Br J Pharmacol* 1983; 80(3): 497-502.
98. Peck MJ, Piper PJ, Williams TJ. The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. *Prostaglandins* 1981; 21(2): 315-321.
99. Czarnetzki BM, Mertensmeier R. In vitro and in vivo chemotaxis of guinea pig leukocytes toward leukotriene B4 and its oxidation products. *Prostaglandins* 1985; 30: 5-11.
100. Palmblad J, Malmsten CL, Uden AM, Radmark O, Engstedt L, Samuelsson B. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. *Blood* 1981; 58(3): 658-661.
101. Chang J, Carlson RP, O'Neill-Davis L, Lamb B, Sharma RN, Lewis AJ. Correlation between mouse skin inflammation induced by arachidonic acid and eicosanoid synthesis. *Inflammation* 1986; 10(3): 205-214.

102. Spector WG, Willoughby DA. Experimental suppression of the acute inflammatory changes in thermal injury. *J Pathol Bacteriol* 1959; 78: 121-132.
103. Spector WG. The granulomatous inflammatory exudate. *Inter Re Exp Pathol* 1969; 8: 1-55.
104. Sim MF. The response of mouse skin to ultraviolet irradiation and its modification by drugs. In: Garattini S, Dukes MNG, editors. *Non-Steroidal Anti-inflammatory Drugs*. Excerpta Medical Internal Congression Service, 1965: 209-213.
105. Boyd JR. *Drug facts and comparison*. Missouai: JB Lippincott Company, 1982: 33-99.
106. Weissmann G, Zurier RB, Spieler PJ, Goldstein IM. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. *J Exp Med* 1971; 134(3): Suppl.
107. Naik SR, Sheth UK. Studies on two new derivatives of N-aralkyl-o-ethoxybenzamides: Part II- biochemical studies on their anti-inflammatory activity. *Indian J Exp Biol* 1978; 166(11): 1175-1179.
108. Friedman LS, Peterson WL. Peptic ulcer and related disorder. In: Fanci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, editors. *Disorder of the gastrointestinal system on Harrison's Principles of Internal Medicine*. 14th ed. New York: McGraw-Hill Inc, 1998: 1597-1610.
109. Morimoto Y, Shimohara K, Oshima S, Sukamoto T. Effects of the new anti-ulcer agent KB-5492 on experimental gastric mucosal lesions and gastric mucosal

- defensive factors, as compared to those of teprenone and cimetidine. *Jpn J Pharmacol* 1991; 57(4): 495-505.
110. Pal S, Nag Chaudhuri AK. Studies on the anti-ulcer activity of a *Bryophyllum pinnatum* leaf extract in experimental animals. *J Ethnopharmacol* 1991; 33(1-2): 97-102.
111. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs-differences and similarities. *N Engl J Med* 1991; 324(24): 1716-1725.
112. Foegh ML, Ramwell PW. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, & related compounds. In: Katzung BG, editor. *Basic and Clinical Pharmacology*. 8th ed. New York: McGraw-Hill Companies, 2001: 311-325.
113. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. *Inflamm Res* 1995; 44(1): 1-10.
114. George PC, Andrew NM. Adrenocorticosteroids & Adrenocortical Antagonists. In: *Basic and Clinical Pharmacology* 8th ed. New York: McGraw-Hill Companies, 2001: 660-678.
115. Raj PP. Pain mechanisms. In: *Pain medicine A Comprehensive Review*. 1st ed. Missouri: Mosby-Year Book, 1996: 12-23.
116. Fields HL. Analgesic Drugs. In: Day W, editor. *Pain*. 1st ed. New York: McGraw-Hill book company, 1987: 272.
117. Abbott FV, Franklin KB, Ludwick RJ, Melzack R. Apparent lack of tolerance in the formalin test suggests different mechanisms for morphine analgesia in different types of pain. *Pharmacol Biochem Behav* 1981; 15(4): 637-640.

118. Abbott FV, Melzack R, Samuel C. Morphine analgesia in tail-flick and formalin pain tests is mediated by different neural systems. *Exp Neurol* 1982; 75(3): 644-651.
119. Alreja M, Mutalik P, Nayar U, Manchanda SK. The formalin test: a tonic pain model in the primate. *Pain* 1984; 20(1): 97-105.
120. Dubuisson D, Dennis SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain* 1977; 4(2): 161-174.
121. Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. *J Neurosci Methods* 1985; 14(1): 69-76.
122. Rosland JH. The formalin test in mice: the influence of ambient temperature. *Pain* 1991; 45(2): 211-216.
123. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. *Pain* 1992; 51(1): 5-17.
124. Heapy CG, Jamicson A, Rusell NJ. Afferent C-fiber and A-delta activity in models of inflammation. *Br J Pharmacol* 1987; 90: 164P.
125. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. *Pain* 1989; 38(3): 347-352.
126. Chen YF, Tsai HY, Wu TS. Anti-inflammatory and analgesic activities from roots of *Angelica pubescens*. *Planta Med* 1995; 61(1): 2-8.

127. Elisabetsky E, Amador TA, Albuquerque RR, Nunes DS, Carvalho AC. Analgesic activity of *Psychotria colorata* (Willd. ex R. & S.) Muell. Arg. alkaloids. *J Ethnopharmacol* 1995; 48(2): 77-83.
128. Santos AR, Filho VC, Yunes RA, Calixto JB. Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus *Phyllanthus*. *Gen Pharmacol* 1995; 26(7): 1499-1506.
129. Flier JF, Underhill LH. The neurologic basis of fever. *New Eng J Med* 1994; 330(26): 1880-1886.
130. Robert II LJ, Morrow JD. Analgesic - antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird L, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill Companies, 2001: 687-731.
131. Sturtino V, Jakubovsky J, Hulin I. Inflammation and fever. In: Pathophysiology Principles of Diseases (Textbook for Medical Students), 1995.
132. Amabeoku GJ, Eagles P, Scott G, Mayeng I, Springfield E. Analgesic and antipyretic effects of *Dodonaea angustifolia* and *Salvia africana-lutea*. *J Ethnopharmacol* 2001; 75(2-3): 117-124.
133. Ushikubi F, Sugimoto Y, Ichikawa A, Narumiya S. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. *Jpn J Pharmacol* 2000; 83(4): 279-285.